Medical Corporation, Syureikai, Tohno Chuo Clinic, Mizunami City, Gifu, Japan.
Int J Chron Obstruct Pulmon Dis. 2024 May 7;19:995-1010. doi: 10.2147/COPD.S441767. eCollection 2024.
To present the preliminarily findings regarding the effects of a herbal medicine, Ninjin'yoeito, on comorbid frailty and sarcopenia in patients with chronic obstructive pulmonary disease (COPD).
Patients with COPD (GOLD II or higher) and fatigue were randomly assigned to Group A (n = 28; no medication for 12 weeks, followed by 12-week administration) or B (n= 25; 24-week continuous administration). Visual analog scale (VAS) symptoms of fatigue, the COPD assessment test (CAT), and the modified Medical Research Council (mMRC) Dyspnea Scale were examined. Physical indices such asknee extension leg strength and walking speed, skeletal muscle mass index (SMI), and respiratory function test were also measured.
VAS fatigue scales in Group B significantly improved after 4, 8, and 12 weeks compared to those in Group A (each p<0.001, respectively). Right and left knee extension leg strength in Group B significantly improved after 12 weeks compared to that in Group A (p=0.042 and p=0.037, respectively). The 1-s walking speed for continued to increase significantly over 24 weeks in Group B (p=0.016, p<0.001, p<0.001, p=0.004, p<0.001, and p<0.001 after 4, 8, 12, 16, 20, and 24 weeks, respectively); it also significantly increased after the administration of Ninjin'yoeito in Group A. In Group B, the SMI significantly increased at 12 weeks in patients with sarcopenia (p=0.025). The CAT scores in Group B significantly improved after 12 weeks compared to those in Group A (p=0.006). The mMRC scores in Group B also significantly improved after 8 and 12 weeks compared to those in Group A (p= 0.045 and p <0.001, respectively). The changes in %FEV1.0 in Group B were significantly improved at 12 and 24 weeks (p=0.039 and p=0.036, respectively).
Overall, Ninjin'yoeito significantly improved patients' quality of life, physical activity, muscle mass, and possibly lung function, suggesting that Ninjin'yoeito may improve frailty and sarcopenia in patients with COPD.
介绍一种草药 Ninjin'yoeito 对慢性阻塞性肺疾病（COPD）合并衰弱和肌少症患者的影响的初步研究结果。
将 COPD（GOLD II 或更高）合并疲劳的患者随机分为 A 组（n = 28；12 周无药物治疗，随后进行 12 周的治疗）或 B 组（n = 25；24 周连续治疗）。评估患者的视觉模拟量表（VAS）疲劳症状、COPD 评估测试（CAT）和改良医学研究委员会（mMRC）呼吸困难量表。还测量了患者的膝关节伸展腿部力量和步行速度等身体指标、骨骼肌质量指数（SMI）和呼吸功能测试。
与 A 组相比，B 组的 VAS 疲劳量表在第 4、8 和 12 周后均显著改善（均 p < 0.001）。B 组的右膝和左膝伸展腿部力量在 12 周后均显著改善（p = 0.042 和 p = 0.037）。B 组的 1 秒步行速度在 24 周内持续显著增加（第 4、8、12、16、20 和 24 周时分别为 p = 0.016、p < 0.001、p < 0.001、p = 0.004、p < 0.001 和 p < 0.001），在 A 组接受 Ninjin'yoeito 治疗后也显著增加。在 B 组中，肌少症患者的 SMI 在 12 周时显著增加（p = 0.025）。与 A 组相比，B 组的 CAT 评分在 12 周后显著改善（p = 0.006）。与 A 组相比，B 组的 mMRC 评分在 8 周和 12 周后也显著改善（p = 0.045 和 p < 0.001）。B 组的 %FEV1.0 变化在 12 周和 24 周时显著改善（p = 0.039 和 p = 0.036）。
总体而言，Ninjin'yoeito 显著改善了患者的生活质量、身体活动能力、肌肉质量，可能还改善了肺功能，提示 Ninjin'yoeito 可能改善 COPD 患者的衰弱和肌少症。
